Not Losing Weight on 2.5mg Mounjaro — and What to Do Next

Step 1, Understand what 2.5mg is actually there to do

There is a common misconception worth clearing up gently: people often assume the first pen is a test to see whether Mounjaro will work for them. That is not quite right. The 2.5mg dose exists because tirzepatide is a potent dual GIP and GLP-1 receptor agonist, and starting low reduces the nausea, vomiting and other gastrointestinal discomfort that can occur if the body meets the full effect without warning. The job of those first four weeks is to settle your system, not to treat your weight.

In the SURMOUNT-1 trial, the results that made headlines (average body-weight reductions of around 20%) were recorded at 15mg after 72 weeks, not at 2.5mg. The licensed schedule begins at 2.5mg and steps up, typically every four weeks, through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg, as described in the NHS patient information for tirzepatide. So if you are not losing weight on 2.5mg Mounjaro, you are, almost certainly, exactly where the clinical sequence expects you to be.

This matters because stopping at this stage (or assuming the medicine does not suit you) means walking away before it has had a proper chance to work. Frustrating, yes. But the evidence base was built on the full titration pathway, not the opener.

Step 2, Recognise what can make even the starter dose harder than expected

A small number of people do experience some early appetite change at 2.5mg, but it tends to be subtle. If you are not feeling much (no reduction in hunger, no real change in how quickly you feel full) that is consistent with how the dose behaves for most people. The dual-receptor action becomes more pronounced as the dose rises.

That said, a few practical factors can blunt whatever early effect there is. Injection technique matters: the pen should be pressed firmly against the skin of the abdomen, thigh or upper arm until a click is heard, then held for ten seconds. An incorrect injection may mean less of the dose is absorbed. Storage temperature matters too, Mounjaro pens should be kept refrigerated between 2°C and 8°C, and the exact guidance on any brief room-temperature window is in the Patient Information Leaflet that comes with your pen, rather than a figure to rely on from any website.

Calorie intake, protein adequacy, sleep and activity levels all interact with GLP-1 class medicines. The NHS recommends that weight-management treatment works alongside a reduced-calorie diet and increased physical activity. At 2.5mg, when appetite suppression is minimal, the lifestyle component carries more of the load. Our weight-loss overview covers what realistic expectations look like across the treatment journey.

Step 3, Know when to raise it with your prescriber

The right time to raise a lack of progress is at your next clinical review, not by adjusting the dose yourself. A prescriber looking at your response to 2.5mg can confirm whether titration to 5mg is appropriate and timely. Tolerance of the current dose, any side effects, your weight trend and your wider health picture all feed into that decision. This is not a box-ticking exercise, it is the point at which the treatment becomes genuinely personalised.

If you want a sense of what response to a higher dose typically looks like, our pages on not losing weight on 5mg Mounjaro and not losing weight on 7.5mg cover the same questions at each stage. For a broader look at why weight loss can stall at any point in the schedule, this page on the reasons behind slow progress at 2.5mg goes deeper on the biology.

If you are already on a higher dose and still not seeing movement, the 5mg stall page or the 7.5mg stall page may be more relevant. Weight loss on GLP-1 medicines is rarely a straight line, and the dose you are on now is rarely the dose where the story ends.

Step 4, What the NICE and NHS evidence actually says about results

NICE's appraisal of tirzepatide, published as TA1026, draws on SURMOUNT trial data involving thousands of adults with obesity. The headline results come from participants who completed the full titration to higher doses over 72 weeks, alongside a reduced-calorie diet and increased activity. NICE does note that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment should be reviewed, but that review point comes much later in the process than the 2.5mg starting pen.

In practical terms, this means the clinical bar for assessing whether Mounjaro is working for you is set at six months and at the highest tolerated dose, not at month one on the starter. Prescribers at services like ours follow that same logic. If you are weighing up what private treatment involves, the Mounjaro pricing page explains what is included. And if you want to understand the full picture of the medicine before your next review, the Mounjaro overview is a good place to start.

If any questions about your treatment are pressing (side effects, uncertainty about whether to continue, anything that feels urgent) speak directly with your prescribing team. At nume, that means reaching our clinical support team, seven days a week.